Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

British Journal of Haematology

Volumn 158, Issue 6, 2012, Pages 727-738

  Sanchez, Eric ^a   Li, Mingjie ^a   Kitto, Alex ^a   Li, Jennifer ^a   Wang, Cathy S ^a   Kirk, Dylan T ^a   Yellin, Ori ^a   Nichols, Cydney M ^a   Dreyer, Marissa P ^a   Ahles, Cameryn P ^a   Robinson, Austin ^b   Madden, Erik ^b   Waterman, Gabriel N ^c   Swift, Regina A ^d   Bonavida, Benjamin ^b   Boccia, Ralph ^e   Vescio, Robert A ^f   Crowley, John ^g   Chen, Haiming ^a   Berenson, James R ^a,d  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d James R Berenson MD Inc   (United States)

^e Center for Cancer and Blood Disorders   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g Cancer Research and Biostatics   (United States)

Author keywords

B cell maturation antigen; In vivo; Multiple myeloma; Serum; Xenografts

Indexed keywords

B CELL MATURATION ANTIGEN; BORTEZOMIB; CYCLOPHOSPHAMIDE; MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CANCER SIZE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MONONUCLEAR CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUPERNATANT; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; B-CELL MATURATION ANTIGEN; BONE MARROW; BORONIC ACIDS; CELL MEMBRANE; CULTURE MEDIA, CONDITIONED; CYCLOPHOSPHAMIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; MICE; MICE, SCID; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PLASMA CELLS; PYRAZINES; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84865530770     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09241.x     Document Type: Article

References (48)

1. Bellucci, R., Alyea, E.P., Chiaretti, S., Wu, C.J., Zorn, E., Weller, E., Wu, B., Canning, C., Schlossman, R., Munshi, N.C., Anderson, K.C. & Ritz, J. (2005) Graft-verus-tumour response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood, 105, 3945-3950.
2. Campbell, R.A. & Berenson, J.R. (2008) Animal models of multiple myeloma and their utility in drug discovery. Current Protocols in Pharmacology, 40, 14.9.1-14.9.22
3. Cheema, G.S., Roschke, V., Hilbert, D.M. & Stohl, W. (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheumatology, 44, 1313-1319.
4. Chiu, A., Xu, W., He, B., Dillon, S.R., Gross, J.A., Sievers, E., Qiao, X., Santini, P., Hyjek, E., Lee, J.W., Cesarman, E., Chadburn, A., Knowles, D.M. & Cerutti, A. (2007) Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood, 109, 729-739.
5. Day, E.S., Cachero, T.G., Qian, F., Sun, Y., Wen, D., Pelletier, M., Hsu, Y.-M. & Whitty, A. (2005) Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry, 44, 1919-1931.
6. Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36, 842-854.
7. Elsawa, S.F., Novak, A.J., Grote, D.M., Ziesmer, S.C., Witzig, T.E., Kyle, R.A., Dillon, S.R., Harder, B., Gross, J.A. & Ansell, S.M. (2006) B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood, 107, 2882-2888.
8. Ghanta, V.K. & Hiramoto, R.N. (1974) Quantitation of toal-body tumour cells (MOPC 104E)-1 subcutaneous model. The Journal of the National Cancer Institute, 52, 1199-1202.
9. Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412-3420.
10. Groom, J., Kalled, S.L., Cutler, A.H., Olson, C., Woodcock, S.A., Schneider, P., Tschopp, J., Cachero, T.G., Batten, M., Wheway, J., Mauri, D., Cavill, D., Gordon, T.P., Mackay, C.R. & Mackay, F. (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. Journal of Clinical Investigation, 109, 59-68.
11. Gross, J.A., Johnston, J., Mudri, S., Enselman, R., Dillon, S.R., Madden, K., Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., Moore, M., Littau, A., Grossman, A., Haugen, H., Foley, K., Blumberg, H., Harrison, K., Kindsvogel, W. & Clegg, C.H. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B cell autoimmune disease. Nature, 404, 995-999.
12. Jones, S.A., Horiuchi, S., Topley, N., Yamamoto, N. & Fuller, G.M. (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. The FASEB Journal, 15, 43-58.
13. Kawano, M., Huang, N., Harada, H., Harada, Y., Sakai, A., Tanaka, H., Iwato, K. & Kuramoto, A. (1993) Identification of immature and mature cells in the bone marrow of human myelomas. Blood, 82, 564-570.
14. Kyle, R.A. (1994) Why better prognostic factors for multiple myeloma are needed. Blood, 83, 1713-1716.
15. Laabi, Y., Gras, M.P., Carbonnel, F., Brouet, J.C., Berger, R., Larsen, C.J. & Tsapis, A. (1992) A new gene, BCM, on chromosome 16 is fused to interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. The EMBO Journal, 11, 3897-3904.
16. Laabi, Y., Gras, M.P., Brouet, J.C., Berger, R., Larsen, C.J. & Tsapis, A. (1994) The BCMA gene, preferentially expressed during lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Research, 22, 1147-1154.
17. Larson, R.S., Sukpanichnant, S., Greer, J.P., Cousar, J.B. & Collins, R.D. (1997) The spectrum of multiple myeloma: diagnostic and biological implications. Human Pathology, 28, 1336-1347.
18. Maia, S., Pelletier, M., Ding, J., Hsu, Y.M., Sallan, S.E., Rao, S.P., Nadler, L.M. & Cardoso, A.A. (2011) Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One, 6, 1-12.
19. McKay, F., Woodcock, S.A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tschopp, J. & Browning, J.L. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. Journal of Experimental Medicine, 190, 1697-1710.
20. Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., Jack, H.M. & Voll, R.E. (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Research, 67, 1783-1792.
21. Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Reme, T., Lugagne, C., Moine, P., Rossi, J.F., Klein, B. & Tarte, K. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood, 103, 3148-3157.
22. Nathans, D., Fahey, J.L. & Potter, M. (1958) The formation of myeloma protein by a mouse plasma cell tumour. Journal of Experimental Medicine, 108, 121-129.
23. Novak, A.J., Darce, J.R., Arendt, B.K., Hardner, B., Henderson, K., Kindsvogel, W., Gross, J.A., Greipp, P.R. & Jelinek, D.F. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood, 103, 689-694.
24. O'Connor, B.P., Raman, V.S., Erickson, L.D., Cook, W.J., Weaver, L.K., Ahonen, C., Lin, L.L., Mantchev, G.T., Bram, R.J. & Noelle, R.J. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. Journal of Experimental Medicine, 199, 91-97.
25. Oki, Y., Georgakis, G., Migone, T.S., Kwak, L.W. & Younes, A. (2005) Serum BLyS level as a prognostic marker in patients with lymphoma. Blood (ASH Annual Meeting Abstracts), 106, 546a.
26. Pelletier, M., Thompson, J.S., Qian, F., Bixler, S.A., Gong, D., Cachero, T., Gilbride, K., Day, E., Zafari, M., Benjamin, C., Gorelik, L., Whitty, A., Kalled, S.L., Ambrose, C. & Hsu, Y.M. (2003) Comparisons of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonist for BAFF. The Journal of Biological Chemistry, 278, 33127-33133.
27. Rajkumar, S.V., Harousseau, J.L., Durie, B., Anderson, K.C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., Jagannath, S., Facon, T., Avet-Loiseau, H., Lonial, S., Palumbo, A., Zonder, J., Ludwig, H., Vesole, D., Sezer, O., Munshi, N.C. & San Miguel, J. On behalf of the International Myeloma Workshop Consensus Panel 1. (2011) Consensus recommendations for the uniform reporting of clinical trials: a report of the International Myeloma Workshop Consensus Panel 1. Blood, 117, 4691-4695.
28. Rennert, P., Schneider, P., Cachero, T.G., Thompson, J., Trabach, L., Hertig, S., Holler, N., Qian, F., Mullen, C., Strauch, K., Browning, J.L., Ambrose, C. & Tschopp, J. (2000) A soluble form of B cell maturation antigen, a receptor for the tumour necrosis family member APRIL, inhibits tumour cell growth. Journal of Experimental Medicine, 192, 1677-1683.
29. Ryan, M.C., Hering, M., Peckham, D., McDonagh, C.F., Brown, L., Kim, K.M., Meyer, D.L., Zabinski, R.F., Grewal, I.S. & Carter, P.J. (2007) Antibody targeting of B-cell maturation antigen on malignant plasma cells. Molecular Cancer Therapeutics, 6, 3009-3018.
30. Salmon, S.E. & Smith, B.A. (1970) Immunoglobulin synthesis and total body cell number in IgG multiple myeloma. Journal of Clinical Investigation, 49, 1114-1121.
31. Sanchez, E., Li, M., Steinberg, J.A., Wang, C., Shen, J., Bonavida, B., Li, Z.W., Chen, H. & Berenson, J.R. (2010) The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. British Journal of Haematology, 148, 569-581.
32. Seshasayee, D., Valdez, P., Yan, M., Dixit, V.M., Tumas, D. & Grewal, I.S. (2003) Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity, 18, 279-288.
33. Shaw, G.R. (2006) Nonsecretory plasma cell myeloma-becoming even more rare with serum light-chain assay. Archives of Pathology & Laboratory Medicine, 130, 1212-1215.
34. Smith, C.A., Farrah, T. & Goodwin, R.G. (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell, 76, 959-962.
35. Stephens, O.W., Zhang, Q., Qu, P., Zhou, Y., Chavan, S., Tian, E., Williams, D.R., Epstein, J., Barlogie, B. & Shaughnessy, Jr, J.D. (2012) An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood, 119, 503-512.
36. Sullivan, P.W. & Salmon, S.E. (1972) Kinetics of tumour growth and regression in IgG multiple myeloma. Journal of Clinical Investigation, 51, 1697-1708.
37. Tanaka, H., Tanabe, O., Iwato, K., Asaoku, H., Ishikawa, H., Nobuyoshi, M., Kawano, M. & Kuramoto, A. (1989) Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells. Blood, 74, 1718-1722.
38. Tassone, P., Neri, P., Carrasco, D.R., Burger, R., Goldmacher, V.S., Fram, R., Munshi, V., Shammas, M.A., Catley, L., Jacob, G.S., Venuta, S., Anderson, K.C. & Munshi, N.C. (2005) A clinically relevant SCID-hu model of human multiple myeloma. Blood, 106, 713-716.
39. The International Myeloma Working Group. (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757.
40. Thompson, J.S., Schneider, P., Kalled, S.L., Wang, L., Lefevre, E.A., Cachero, T.G., MacKay, F., Bixler, S.A., Zafari, M., Liu, Z.-Y., Woodcock, S.A., Qian, F., Batten, M., Madry, C., Richard, Y., Benjamin, C.D., Browning, J.L., Andreas, T., Tschopp, J. & Ambrose, C. (2000) BAFF binds to the tumour necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. Journal of Experimental Medicine, 192, 129-135.
41. Thompson, J.S., Bixler, S.A., Qian, F., Vora, K., Scott, M.L., Cachero, T.G., Hession, C., Schneider, P., Sizing, I.D., Mullin, C., Strauch, K., Zafari, M., Benjamin, C.D., Tschopp, J., Browning, J.L. & Ambrose, C. (2001) BAFFR, a newly identified TNF receptor that specifically interacts with BAFF. Science, 293, 2108-2111.
42. Varfolomeev, E., Kischkel, F., Martin, F., Seshasayee, D., Wang, H., Lawrence, D., Olsson, D., Tom, L., Erickson, S., French, D., Schow, P., Grewal, I.S. & Ashkenazi, A. (2004) APRIL-deficient mice have normal immune system development. Molecular Cellular Biology, 24, 997-1006.
43. Wu, Y., Bressette, D., Carrell, J.A., Kaufman, T., Feng, P., Taylor, K., Gan, Y., Cho, Y.H., Garcia, A.D., Gollatz, E., Dimke, D., LaFleur, D., Migone, T.S., Nardelli, B., Wei, P., Ruben, S.M., Ullrich, S.J., Olsen, H.S., Kanakaraj, P., Moore, P.A. & Baker, K.P. (2000) Tumour necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for the TNF family members APRIL and BLyS. Journal of Biological Chemistry, 275, 35478-35485.
44. Xu, S. & Lam, K.P. (2001) B-cell maturation protein, which binds the tumour necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Molecular Cellular Biology, 21, 4067-4074.
45. Yan, M., Brady, J.R., Chan, B., Lee, W.P., Hsu, B., Harless, S., Cancro, M., Grewal, I.S. & Dixit, V.M. (2001) Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Current Biology, 11, 1547-1552.
46. Yu, G., Boone, T., Delaney, J., Hawkins, N., Kelly, M., Ramakrishnan, M., McCabe, S., Qiu, W.R., Kornuc, M., Xia, X.Z., Guo, J., Stolina, M., Boyle, W.J., Sarosi, I., Hsu, H., Senaldi, G. & Theill, L.E. (2000) APRIL and TALL-1 and receptors and BCMA and TACI: system for regulating humoral immunity. Nature Immunology, 1, 252-256.
47. Zaanen, H.C.T., Lokhorst, H.M., Aarden, L.A., Rensink, H.J.A.M., Warnaar, S.O., Van Der Lelie, J. & Van Oers, M.J.H. (1998) Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. British Journal of Haematology, 102, 783-790.
48. Zhang, J., Roschke, V., Baker, K.P., Wang, Z., Alarcon, G.S., Fessler, B.J., Bastian, H., Kimberly, R.P. & Zhou, T. (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. Journal of Immunology, 166, 6-10.